Illumina (NASDAQ:ILMN) Director Keith Meister Sells 138,379 Shares of Stock

Illumina, Inc. (NASDAQ:ILMN) Director Keith Meister sold 138,379 shares of the firm’s stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $228.89, for a total value of $31,673,569.31. Following the transaction, the director owned 1,033,910 shares in the company, valued at $236,651,659.90. The trade was a 11.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Illumina Price Performance

Shares of ILMN stock opened at $227.69 on Friday. Illumina, Inc. has a twelve month low of $88.00 and a twelve month high of $231.81. The stock has a market capitalization of $34.38 billion, a price-to-earnings ratio of 42.48, a P/E/G ratio of 3.16 and a beta of 1.45. The stock has a fifty day simple moving average of $192.98 and a two-hundred day simple moving average of $155.18. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating the consensus estimate of $1.23 by $0.08. The firm had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The business’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter last year, the firm posted $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, analysts predict that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Institutional Trading of Illumina

A number of institutional investors have recently made changes to their positions in the business. California State Teachers Retirement System increased its position in Illumina by 16,869.5% during the 2nd quarter. California State Teachers Retirement System now owns 40,144,099 shares of the life sciences company’s stock valued at $7,058,537,000 after buying an additional 39,907,533 shares in the last quarter. BlackRock Inc. acquired a new stake in Illumina in the second quarter worth about $3,374,423,000. Primecap Management Co. CA acquired a new stake in Illumina in the second quarter worth about $617,981,000. Jupiter Topco LLC purchased a new stake in shares of Illumina during the second quarter worth about $358,652,000. Finally, WCM Investment Management LLC grew its stake in shares of Illumina by 45.5% during the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock worth $715,579,000 after acquiring an additional 1,851,848 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analyst Ratings Changes

ILMN has been the subject of several research reports. Daiwa Securities Group raised shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price target for the company in a research report on Thursday, May 14th. JPMorgan Chase & Co. boosted their price objective on shares of Illumina from $220.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Canaccord Genuity Group increased their target price on Illumina from $190.00 to $205.00 and gave the company a “hold” rating in a research report on Monday, August 3rd. Weiss Ratings upgraded Illumina from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, June 3rd. Finally, Guggenheim boosted their price target on Illumina from $200.00 to $226.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $188.40.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.